rs267606613
Variant summary
Our verdict is Likely pathogenic. The variant received 5 ACMG points: 5P and 0B. PVS1_ModeratePM6PM2_Supporting
This summary comes from the ClinGen Evidence Repository: The m.9952G>A (p.W249Term) variant in MT-CO3 has been reported in one individual with mitochondrial disease to date, in a 36-year-old woman with encephalopathy, myopathy, exercise-induced myalgia, muscle weakness, and migraines, with onset of symptoms at age 17 years (PMID:9634511). Muscle biopsy showed reduced COX activity and decreased complex IV activity. The variant was present at 57% heteroplasmy in muscle and was undetectable in blood and skin. The variant was absent in muscle from her mother (PM6; PMID:9634511). This variant causes a premature stop in the MT-CO3 gene resulting in truncation of 5% of the protein (PVS1_moderate). This variant is absent in the MITOMAP GenBank dataset, gnomAD v3.1.2, and the Helix dataset (PM2_supporting). There are no in silico predictors for this type of variant in mitochondrial DNA. Single fiber testing showed higher levels of the variant in COX negative fibers (56.2%, n=24) than in COX positive fibers (10.1%, n=21), p<0.0002 (PS3_supporting, PMID:9634511). In summary, this variant meets criteria to be classified as likely pathogenic for primary mitochondrial disease inherited in a mitochondrial manner. This classification was approved by the NICHD/NINDS U24 ClinGen Mitochondrial Disease Variant Curation Expert Panel on February 26, 2024. Mitochondrial DNA-specific ACMG/AMP criteria applied (PMID:32906214): PM6, PVS1_moderate, PM2_supporting, PS3_supporting. LINK:https://erepo.genome.network/evrepo/ui/classification/CA120601/MONDO:0044970/015
Frequency
Consequence
ENST00000362079.2 stop_gained
Scores
Clinical Significance
Conservation
Publications
Genome browser will be placed here
ACMG classification
Our verdict: Likely_pathogenic. The variant received 5 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| COX3 | unassigned_transcript_4806 | c.746G>A | p.Trp249* | stop_gained | Exon 1 of 1 | |||
| ND3 | unassigned_transcript_4808 | c.-107G>A | upstream_gene_variant | |||||
| TRNG | unassigned_transcript_4807 | c.-39G>A | upstream_gene_variant |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| MT-CO3 | ENST00000362079.2 | c.746G>A | p.Trp249* | stop_gained | Exon 1 of 1 | 6 | ENSP00000354982.2 | |||
| MT-ND3 | ENST00000361227.2 | c.-107G>A | upstream_gene_variant | 6 | ENSP00000355206.2 | |||||
| MT-TG | ENST00000387429.1 | n.-39G>A | upstream_gene_variant | 6 |
Frequencies
Mitomap
ClinVar
Submissions by phenotype
Mitochondrial complex IV deficiency, nuclear type 1 Pathogenic:1
- -
Mitochondrial disease Pathogenic:1
The m.9952G>A (p.W249Term) variant in MT-CO3 has been reported in one individual with mitochondrial disease to date, in a 36-year-old woman with encephalopathy, myopathy, exercise-induced myalgia, muscle weakness, and migraines, with onset of symptoms at age 17 years (PMID: 9634511). Muscle biopsy showed reduced COX activity and decreased complex IV activity. The variant was present at 57% heteroplasmy in muscle and was undetectable in blood and skin. The variant was absent in muscle from her mother (PM6; PMID: 9634511). This variant causes a premature stop in the MT-CO3 gene resulting in truncation of 5% of the protein (PVS1_moderate). This variant is absent in the MITOMAP GenBank dataset, gnomAD v3.1.2, and the Helix dataset (PM2_supporting). There are no in silico predictors for this type of variant in mitochondrial DNA. Single fiber testing showed higher levels of the variant in COX negative fibers (56.2%, n=24) than in COX positive fibers (10.1%, n=21), p<0.0002 (PS3_supporting, PMID: 9634511). In summary, this variant meets criteria to be classified as likely pathogenic for primary mitochondrial disease inherited in a mitochondrial manner. This classification was approved by the NICHD/NINDS U24 ClinGen Mitochondrial Disease Variant Curation Expert Panel on February 26, 2024. Mitochondrial DNA-specific ACMG/AMP criteria applied (PMID: 32906214): PM6, PVS1_moderate, PM2_supporting, PS3_supporting. -
Computational scores
Source: